Double-Blind Placebo (Pbo)-Controlled Randomized Phase Iii Trial Evaluating First-Line Ipatasertib (Ipat) Combined With Paclitaxel (Pac) For Pik3ca/Akt1/Pten-Altered Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer (Atnbc): Primary Results From Ipatunity130 Cohort A
CANCER RESEARCH(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要